Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Hpv1618 L1 Vlp As04 Vaccine

Research Leaders

5 sponsors active, led by Jhpiego

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07200414Not ApplicableCompletedPrimary

Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)

NCT00572000Not ApplicableUnknownPrimary

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule

Showing all 2 trials

Research Network

Common Treatments

  • Hpv1618 L1 Vlp As04 Vaccine1
  • Integrated Adolescent Health Package1
  • Routine Government Health Services1

Active Sponsors

  • Jhpiego1
  • Direct Consulting and Logistics1
  • National Institute for Control of Vaccine and Biologicals1
  • Johns Hopkins Bloomberg School of Public Health1
  • Gavi, The Vaccine Alliance1

Top Investigators

Related Conditions

  • Adolescent Health Services1
  • Human Papillomavirus Hpv Infections1
  • Human Papillomavirus Hpv Vaccines1

Activity Timeline